U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185880) titled 'A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients' on Aug. 19.
Brief Summary: The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard of care treatment.
Initially, participants with newly diagnosed glioblastoma will be given different doses of MT-125 in combination with radiotherapy (RT) with the goal of identifying the highest tolerated dose.
Up to 36 people with glioblastoma who are at least18 years old are being invited to ...